Prostate cancer trials recruiting in Oregon

All Prostate cancer trials nationally

Cities in Oregon

Recruiting trials in Oregon

• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
  NCT07543055 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06879041 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
  NCT05593497 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
  NCT06095089 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Portland
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Springfield
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07225946 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Springfield
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07164443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Portland, Springfield
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
  NCT05652686 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Portland
• A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
  NCT06457919 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Salem
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
  NCT03972657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Portland
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
  NCT07611110 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
  NCT05422911 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
  NCT05939414 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Oregon: Springfield
• Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
  NCT05806515 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Oregon: Baker City, Bend, Clackamas, Coos Bay
• Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
  NCT04038502 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Oregon: Baker City, Bend, Clackamas, Coos Bay
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  NCT06592924 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Baker City, Bend, Clackamas, Coos Bay
• EMBRACE: Exercising Together
  NCT06049355 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Portland
• Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
  NCT06257693 · Phase: Phase 1 · Ages: 21 Years and older · Sex: Male · Oregon: Portland
• Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
  NCT07080242 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Portland
• Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
  NCT05919329 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Portland
• GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer
  NCT07504835 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years and older · Sex: Male · Oregon: Portland
• High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
  NCT05011383 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
  NCT07569926 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• International Registry for Men With Advanced Prostate Cancer (IRONMAN)
  NCT03151629 · Phase: Not specified · Ages: 21 Years and older · Sex: Male · Oregon: Portland
• Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
  NCT06011499 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Portland
• MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
  NCT05710380 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
  NCT06134232 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Oregon: Springfield
• Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
  NCT03753243 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
  NCT07590934 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: Male · Oregon: Portland
• Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
  NCT06056830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Springfield
• Precision-Based Genomics in Prostate Cancer
  NCT04706663 · Phase: Not specified · Ages: 18 Years to 120 Years · Sex: Male · Oregon: Portland
• Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
  NCT04472338 · Phase: Not specified · Ages: 40 Years and older · Sex: Male · Oregon: Portland
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Oregon: Portland
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Gresham, Portland
• Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
  NCT05417594 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · Oregon: Portland
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
  NCT05489211 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · Oregon: Portland
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  NCT06136624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Portland
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Portland
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Portland
• Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
  NCT07200830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  NCT05946213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Bend, Clackamas, Portland
• Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
  NCT06470243 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Baker City, Ontario
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
  NCT03866382 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oregon: Baker City, Bend, Clackamas, Coos Bay
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Oregon: Portland
• The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
  NCT06520345 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
  NCT04423211 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Oregon: Bend, Clackamas, Coos Bay, Gresham
• ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
  NCT04986423 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Oregon: Portland
• cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
  NCT05366881 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · Oregon: Portland